Payment overview · 2025
General Payments
$169,687.58
163 reported records · 12 companies
Healthcare provider profile · identity verified
Peter Toth, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STERLING, IL · NPI 1861572869
Verified facts
What the public records show
CMS Open Payments records show Peter Toth, M.D. received $169,687.58 in general payments during 2025 across 163 reported records.
Lilly USA, LLC accounted for 46.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Vascepa.
Amarin Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vascepa as an associated drug or biological on 325 records involving 226 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vascepa by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77,986.70 | 46.0% | 79 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43,153.81 | 25.4% | 32 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30,809.88 | 18.2% | 23 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13,729.05 | 8.1% | 16 | 2025 |
| Amarin Pharma, Inc. | Unresolved — no canonical attribution shown | $3,575.00 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $150.63 | 0.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $136.93 | 0.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.68 | 0.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.18 | 0.0% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.05 | 0.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.65 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.02 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $119,656.94 | 57 |
| Consulting Fee | $28,698.41 | 10 |
| Travel and Lodging | $18,551.46 | 41 |
| Food and Beverage | $2,760.55 | 54 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67,137.96 | 66 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43,153.81 | 32 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30,726.99 | 19 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $8,116.25 | 6 | 2025 |
Source payment records
|
|||||
| Vascepa Normalized: vascepa |
Drug | Amarin Pharma, Inc. | $3,575.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $150.63 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $136.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.68 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $8.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 194 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
| Vascepa vascepa |
2025 | Vascepa | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amarin Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Vascepa open payments reported associated product |
CMS Open Payments — General Payments 325 supporting records · 226 recipient NPIs · example record 1237615661 |
Vascepa · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
194 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 881 | 240 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 587 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 562 | 153 |
| Metformin Hcl | Metformin Hcl | 442 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 111 |
| Ezetimibe | Ezetimibe | 299 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 73 |
| Furosemide | Furosemide | 277 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 75 |
| Lisinopril | Lisinopril | 259 | 70 |
| Potassium Chloride | Potassium Chloride | 256 | 74 |
| Gabapentin | Gabapentin | 246 | 53 |
| Carvedilol | Carvedilol | 236 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 71 |
| Losartan Potassium | Losartan Potassium | 223 | 59 |
| Alprazolam | Alprazolam | 219 | 49 |
| Jardiance | Empagliflozin | 194 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 49 |
| Sertraline Hcl | Sertraline Hcl | 164 | 38 |
| Eliquis | Apixaban | 158 | 33 |
| Omeprazole | Omeprazole | 154 | 44 |
| Ozempic | Semaglutide | 147 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 127 | 25 |
| Repatha Sureclick | Evolocumab | 124 | 19 |
| Celecoxib | Celecoxib | 122 | 32 |
| Spironolactone | Spironolactone | 118 | 32 |
| Ramipril | Ramipril | 116 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 32 |
| Valsartan | Valsartan | 111 | 30 |
| Prednisone | Prednisone | 103 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 35 |
| Fenofibrate | Fenofibrate | 96 | 28 |
| Montelukast Sodium | Montelukast Sodium | 88 | 24 |
| Tramadol Hcl | Tramadol Hcl | 81 | 20 |
| Simvastatin | Simvastatin | 80 | 23 |
| Lorazepam | Lorazepam | 76 | 11 |
| Allopurinol | Allopurinol | 75 | 21 |
| Bupropion Xl | Bupropion Hcl | 74 | 17 |
| Donepezil Hcl | Donepezil Hcl | 73 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 73 | 21 |
| Clonazepam | Clonazepam | 67 | 17 |
| Entresto | Sacubitril/Valsartan | 66 | 14 |
| Meloxicam | Meloxicam | 66 | 20 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Diclofenac Sodium Er | Diclofenac Sodium | 63 | 15 |
| Enalapril Maleate | Enalapril Maleate | 63 | 15 |
| Levofloxacin | Levofloxacin | 59 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Nabumetone | Nabumetone | 57 | 16 |
| Buspirone Hcl | Buspirone Hcl | 56 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 13 |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 53 | 16 |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 12 |
| Praluent Pen | Alirocumab | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | 12 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Xarelto | Rivaroxaban | 46 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | 12 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 11 |
| Cefuroxime | Cefuroxime Axetil | 36 | 31 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Glipizide | Glipizide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Belsomra | Suvorexant | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 24 |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 17 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 17 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Digoxin | Digoxin | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169,687.58 · 163 records | Lilly USA, LLC | CAPLYTA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, Ohtuvayre, Ozempic, REPATHA, The Cologuard Plus Collection Kit, Vascepa, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amarin Pharma, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error